0026-895X/04/6501-235-243$20.00
Mol Pharmacol 65:235-243, 2004
Quantitative Effects on c-Jun N-Terminal Protein Kinase Signaling Determine Synergistic Interaction of Cisplatin and 17-Allylamino-17-Demethoxygeldanamycin in Colon Cancer Cell Lines
Irina A. Vasilevskaya,
Tatiana V. Rakitina, and
Peter J. O'Dwyer
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania
We investigated the effects of cisplatin and the hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-AAG) in combination in a panel of human colon adenocarcinoma cell lines that differ in their p53 and mismatch repair status. Analysis of cytotoxicity after combined treatment revealed additive effects of cisplatin and 17-AAG in the HCT 116, DLD1, and SW480 cell lines and antagonism in HT-29 cells. Clonogenic assays demonstrated antagonism in HT-29, an additive effect in SW480, and synergism in HCT 116 and DLD1 cell lines. Analysis of signaling pathways revealed that cisplatin-induced activation of c-Jun N-terminal kinase (JNK) was fully blocked by 17-AAG in HT-29 and SW480 cells, whereas in HCT 116 and DLD1 cells it was inhibited only partially. The activation of caspases was also more pronounced in DLD1 and HCT 116 cell lines. These data suggested that a minimal level of apoptotic signaling through JNK was required for synergism with this combination. To test this hypothesis, we used the specific JNK inhibitor SP600125; when JNK was inhibited pharmacologically in HCT 116 and DLD1 cells, they demonstrated increased survival in clonogenic assays. Alternatively, sustained activation of JNK pathway led to an increase of the cytotoxicity of the cisplatin/17-AAG combination in HT-29 cells. Taken together, these data suggest that the synergistic interaction of this combination in colon cancer cell lines depends on the effect exerted by 17-AAG on cisplatin-induced signaling through JNK and associated pathways leading to cell death. An implication of that finding is that quantitative effects of signaling inhibitors may be critical for their ability to reverse cisplatin resistance.
Received July 24, 2003;
accepted October 10, 2003
Address correspondence to: Dr. Irina A. Vasilevskaya, University of Pennsylvania, 1020 BRB II/III, 421 Curie Blvd., Philadelphia, PA 19104. E-mail: vasilevs{at}mail.med.upenn.edu
This article has been cited by other articles:

|
 |

|
 |
 
S. Fernandez de Mattos, P. Villalonga, J. Clardy, and E. W-F. Lam
FOXO3a mediates the cytotoxic effects of cisplatin in colon cancer cells
Mol. Cancer Ther.,
October 1, 2008;
7(10):
3237 - 3246.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Peklak-Scott, P. K. Smitherman, A. J. Townsend, and C. S. Morrow
Role of glutathione S-transferase P1-1 in the cellular detoxification of cisplatin
Mol. Cancer Ther.,
October 1, 2008;
7(10):
3247 - 3255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. K. McCollum, K. B. Lukasiewicz, C. J. TenEyck, W. L. Lingle, D. O. Toft, and C. Erlichman
Cisplatin abrogates the geldanamycin-induced heat shock response
Mol. Cancer Ther.,
October 1, 2008;
7(10):
3256 - 3264.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. A. Vasilevskaya, M. Selvakumaran, and P. J. O'Dwyer
Disruption of Signaling through SEK1 and MKK7 Yields Differential Responses in Hypoxic Colon Cancer Cells Treated with Oxaliplatin
Mol. Pharmacol.,
July 1, 2008;
74(1):
246 - 254.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. D. C. Francescato, R. S. Costa, F. B. Junior, and T. M. Coimbra
Effect of JNK inhibition on cisplatin-induced renal damage
Nephrol. Dial. Transplant.,
August 1, 2007;
22(8):
2138 - 2148.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Matsui, S. Ueda, J. Watanabe, I. Kuwabara, O. Ogawa, and H. Nishiyama
Sensitizing Effect of Galectin-7 in Urothelial Cancer to Cisplatin through the Accumulation of Intracellular Reactive Oxygen Species
Cancer Res.,
February 1, 2007;
67(3):
1212 - 1220.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Sain, B. Krishnan, M. G. Ormerod, A. De Rienzo, W. M. Liu, S. B. Kaye, P. Workman, and A. L. Jackman
Potentiation of paclitaxel activity by the HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma cell lines with high levels of activated AKT
Mol. Cancer Ther.,
May 1, 2006;
5(5):
1197 - 1208.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Schmitt, L. Maingret, P.-E. Puig, A.-L. Rerole, F. Ghiringhelli, A. Hammann, E. Solary, G. Kroemer, and C. Garrido
Heat shock protein 70 neutralization exerts potent antitumor effects in animal models of colon cancer and melanoma.
Cancer Res.,
April 15, 2006;
66(8):
4191 - 4197.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
X. Wang, W. Ju, J. Renouard, J. Aden, S. A. Belinsky, and Y. Lin
17-Allylamino-17-Demethoxygeldanamycin Synergistically Potentiates Tumor Necrosis Factor-Induced Lung Cancer Cell Death by Blocking the Nuclear Factor-{kappa}B Pathway
Cancer Res.,
January 15, 2006;
66(2):
1089 - 1095.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 by the American Society for Pharmacology and Experimental Therapeutics